At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 293 enrolled
Drug / intervention
desogestrel/ethinyl estradiol and ethinyl estradiol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemosatic Parameters in Healthy Women
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Jul 6, 2011·Updated Dec 6, 2021
In Brief
A Phase 2 clinical trial evaluating desogestrel/ethinyl estradiol and ethinyl estradiol and desogestrel/ethinyl estradiol for Hemostasis and Oral Contraceptive. Completed, enrolled 293 participants across 27 sites in 4 countries.
Detailed Summary
This study is being conducted to evaluate the impact of DR-102, a 28-day oral contraceptive compared to a standard 28-day oral contraceptive regimen on hemostatic parameters in healthy women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemostasis, Oral Contraceptive
CountriesGermany, Israel, Italy, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartOct 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedJul 6, 2011
Enrollment StartOct 31, 2011
Primary CompletionSep 30, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.0 years ago
Interventions
desogestrel/ethinyl estradiol and ethinyl estradioldrug
desogestrel/ethinyl estradioldrug